Skip to main content
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in:

01-12-2021 | Systemic Therapy | Breast Oncology

Surgery of the Primary Tumor in De Novo Metastatic Breast Cancer Confers No Survival Benefit

Authors: Sridevi Murali-Nanavati, MS (Gen Surg), HBNI fellow in Breast Oncology (TMH), Nita S. Nair, DNB (Gen Surg), MRCS (Ed), MCh (Surg Onco), Rajendra Badwe, MS (Gen Surg)

Published in: Annals of Surgical Oncology | Special Issue 3/2021

Login to get access

Excerpt

The benefit of locoregional therapy (LRT) for de novo metastatic breast cancer (dMBC) has been challenged in the past through various retrospective and prospective audits. Many of these studies reported that younger women with hormone receptor-positive (HR+) disease, fewer sites of metastasis, and bone-only metastasis appeared to benefit from local control. This benefit could be attributed to a consistent bias in patient selection for these studies.1 …
Literature
1.
Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery. 2002;132:620–6 (discussion 626–7).CrossRef
2.
Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16:1380–8.CrossRef
3.
Soran A, Ozmen V, Ozbas S, et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01. Ann Surg Oncol. 2018;25:3141–9.CrossRef
4.
Khan SA, Zhao F, Solin LJ, et al. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: a trial of the ECOG-ACRIN Research Group (E2108). J Clin Oncol. 2020;38(18 Suppl):LBA2–5.CrossRef
5.
6.
Reinhorn D, Mutai R, Yerushalmi R, Moore A, Amir E, Goldvaser H. Locoregional therapy in de novo metastatic breast cancer: systemic review and meta-analysis. Breast. 2021;58:173–81.CrossRef
7.
Stahl K, Wong W, Dodge D, et al. Benefits of surgical treatment of stage IV breast cancer for patients with known hormone receptor and HER2 status. Ann Surg Oncol. 2021;28:2646–58.CrossRef
8.
Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 2015;1:1325–32.CrossRef
9.
Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res. 1989;49:1996–2001.PubMed
10.
Fisher B, Fisher ER. Experimental evidence in support of the dormant tumor cell. Science. 1959;130:918–9.CrossRef
11.
O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79:315–28.CrossRef
Metadata
Title
Surgery of the Primary Tumor in De Novo Metastatic Breast Cancer Confers No Survival Benefit
Authors
Sridevi Murali-Nanavati, MS (Gen Surg), HBNI fellow in Breast Oncology (TMH)
Nita S. Nair, DNB (Gen Surg), MRCS (Ed), MCh (Surg Onco)
Rajendra Badwe, MS (Gen Surg)
Publication date
01-12-2021
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue Special Issue 3/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-021-10887-1

Other articles of this Special Issue 3/2021

ASO Visual Abstract: Cancer in the Shadow of COVID: Early-Stage Breast and Prostate Cancer Patient Perspectives on Surgical Delays Due to COVID-19

  • ASO Visual Abstract

Correction to: Time-Driven Activity-Based Costing in Breast Cancer Care Delivery

ASO Visual Abstract: The Prognostic Value of Lymph Node Ratio in Locally Advanced Esophageal Cancer Patients Who Received Neoadjuvant Chemotherapy

  • ASO Visual Abstract

ASO Visual Abstract: Exposure to Blood Components and Inflammation Contribute to Pancreatic Cancer Progression

  • ASO Visual Abstract

Reply: The Effect of Primary Surgery in Patients with Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-center, Registry Study

Does Total Neoadjuvant Treatment Improve Overall Survival in Rectal Cancer? No, It Does Not

SPONSORED

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by:
  • Viatris
Developed by: Springer Healthcare
Watch now
Video
Image Credits